Press releases, workshop summaries, and editorials

The Accelerating Medicines Partnership Parkinson's disease (AMP PD) program, launched on Jan 30, 2018, is the most ambitious initiative so far to find a cure for Parkinson's disease. Formed by the US National Institutes of Health (NIH), the US Food and Drug Administration (FDA), five biopharmaceutical and life science companies, and the Michael J. Fox Foundation, this partnership is focused on discovering novel therapeutic targets and on developing biomarkers to help validate existing therapeutic targets for Parkinson's disease.

“Advancing treatments for Parkinson’s disease is hampered by insufficient understanding of biological networks; drugs aimed at seemingly promising therapeutic targets fail in clinical trials,” said NIH Director Francis S. Collins, M.D., Ph.D. “By combining our expertise and resources, AMP PD partners hope to increase our collective odds of success in accelerating the development of effective treatments for a million Americans who suffer from this debilitating disease.”

On August 8-9, 2016, representatives from NIH,  Principal Investigators (PIs), advocacy groups, industry, as well as clinical and data management experts from each project sponsored under the National Institute of Neurological Disorders and Stroke (NINDS) Parkinson’s Disease (PD) Biomarkers Program (PDBP) met to discuss progress over the last twelve months in addition to current and future plans for the program. 

On August 8-9, 2016, representatives from NIH,  Principal Investigators (PIs), advocacy groups, industry, as well as clinical and data management experts from each project sponsored under the National Institute of Neurological Disorders and Stroke (NINDS) Parkinson’s Disease (PD) Biomarkers Program (PDBP) met to discuss progress over the last twelve months in addition to current and future plans for the program.